AbCellera (ABCL) CFO Andrew Booth Buys 37,200 Shares

What Happened
Andrew Booth, Chief Financial Officer of AbCellera Biologics (ABCL), reported an acquisition of 37,200 shares on August 14, 2026. The shares were acquired at $10.32 each for a total reported outlay of $383,904 (transaction code P — purchase). A purchase is generally regarded as a more informative insider signal than a routine sale, though it does not prove future stock performance.

Key Details

• Transaction date: 2026-08-14; Price: $10.32 per share; Shares acquired: 37,200; Total value: $383,904.
• Transaction type/code: P = Purchase (open-market or private purchase as noted on the Form 4).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Reported with the same period date (2026-08-14), indicating the Form 4 was filed promptly.
• Footnotes/conditions: None noted in the provided data (no 10b5-1 plan, tax withholding, or cashless exercise indicated).

Context
This was a direct purchase of company stock (not an option exercise, gift, or award). Insider purchases can signal confidence but may be driven by personal portfolio reasons; they should be considered alongside other filings, company fundamentals, and market context.